Hims & Hers Health (NYSE:HIMS) shares were on a massive run, but that momentum hit a wall recently. Since its peak on ...

The second group, so-called "Constrained Losers," are those hard-to-short stocks that have lost the most over the trailing year. The professors found that these stocks also lag the market, but for a ...

Shares in telehealth business Hims & Hers Health (HIMS) dropped over 6% today after reports that it and peers are marketing ...

Hims & Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling them to access high-quality medical care for numerous conditions ...

Roller-coaster healthcare stock Hims & Hers Health (NYSE: HIMS), whose stock got devastated last week by worries that it ...

Bristol Myers Squibb said it will acquire its struggling CAR-T partner 2Seventy Bio for $286 million, or $102 million net of ...

Hims & Hers Health has called time on Apostrophe, its personalised acne treatments business. The San Francisco-based ...

Hims & Hers (NYSE: HIMS) is taking investors on a roller-coaster ride in 2025. Where to invest $1,000 right now? Our analyst ...

Apostrophe, a Bay Area telehealth company focused on skin care, shut down after almost four years under the Hims & Hers ...

Citigroup reiterated their sell rating on shares of Hims & Hers Health (NYSE:HIMS – Free Report) in a research report report published on Thursday,Benzinga reports. They currently have a $27.00 price ...

Hims & Hers generated $1.5 billion in revenue in 2024, reflecting a 69% year-over-year increase. See why I rate HIMS stock a ...

Hims & Hers Health will shut down Apostrophe, its personalized acne treatments dermatology business, the company said on Friday. Apostrophe is being shut down to “simplify its (company’s) dermatology ...